Abstract
Human papillomaviruses (HPV) are the causative agents of cervical cancer, the third
most common cancer in women. The development of prophylactic HPV vaccines Gardasil®
and Cervarix® targeting the major oncogenic HPV types is now the frontline of cervical
cancer prevention. Both vaccines have been proven to be highly effective and safe
although there are still open questions about their target population, cross-protection,
and long-term efficacy. The main limitation for a worldwide implementation of Gardasil®
and Cervarix® is their high cost. To develop more affordable vaccines research groups
are concentrated in new formulations with different antigens including capsomeres,
the minor capsid protein L2 and DNA. In this article we describe the vaccines' impact
on HPV-associated disease, the main open questions about the marketed vaccines, and
current efforts for the development of second-generation vaccines.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinics in DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Chapter 2: The burden of HPV-related cancers.Vaccine. 2006; 24 (S3/11-25)
- Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes.Semin Cancer Biol. 1999; 9: 405-411
- Hepatocellular carcinoma in children.Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998; 39: 366-370
- Developmental history of HPV prophylactic vaccines.in: Plotkin S.A. History of Vaccine Development. Springer Science+Business Media, Philadelphia2011: 265-284
- Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments.Virology. 2010; 401: 70-79
- Quantifying the phylodynamic forces driving papillomavirus evolution.Mol Biol Evol. 2011; 28: 2101-2113
- Cutaneous human papillomaviruses persist on healthy skin.J Invest Dermatol. 2007; 127: 116-119
- Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers.Int J Cancer. 2008; 123: 2337-2342
- Papillomaviruses and cancer: From basic studies to clinical application.Nat Rev Cancer. 2002; 2: 342-350
- Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med. 2003; 348: 518-527
- HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.EMBO J. 1989; 8: 3905-3910
- Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA.Oncogene. 1987; 1: 251-256
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.Cell. 1990; 63: 1129-1136
- A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.EMBO J. 1991; 10: 4129-4135
- Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins.Mol Cell Biol. 1993; 13: 4918-4927
- The human papilloma virus—16 E7 oncoprotein is able to bind to the retinoblastoma gene product.Science. 1989; 243: 934-937
- The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.J Virol. 1989; 63: 4417-4421
- Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.Nature. 1985; 314: 111-114
- Therapeutic vaccination for HPV induced cervical cancers.Dis Markers. 2007; 23: 337-352
- Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.Proc Natl Acad Sci U S A. 1992; 89: 12180-12184
- Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles.J Virol. 1993; 67: 1936-1944
- Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.J Virol. 1993; 67: 315-322
- Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.Mol Cell. 2000; 5: 557-567
- Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.Biophys J. 1991; 60: 1445-1456
- The value of vaccination: a global perspective.Vaccine. 2003; 21: 4105-4117
- Chapter 11: HPV vaccines: Commercial research & development.Vaccine. 2006; 24 (S3/99-105)
- Strategien zur Entwicklung einer Vakzine der zweiten Generation gegen das humane Papillomavirus Typ 16. Combined Faculties for Natural Sciences and for Mathematics. Ruperto-Carola University of Heidelberg, Germany2007: 164 (Dissertation)
- Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.J Virol. 1996; 70: 960-965
- Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.J Virol. 1995; 69: 3959-3963
- Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.Proc Natl Acad Sci U S A. 1995; 92: 11553-11557
- Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.Virology. 1996; 219: 37-44
- Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].Drugs. 2008; 68: 359-372
- Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).Drugs. 2006; 66 ([discussion 1272–1273]): 1263-1271
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial.Lancet. 2009; 373: 1949-1957
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial.Lancet. 2004; 364: 1757-1765
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial.Lancet Oncol. 2005; 6: 271-278
- Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.N Engl J Med. 2007; 356: 1928-1943
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial.Lancet. 2007; 369: 2161-2170
- Safety of quadrivalent human papillomavirus vaccine.J Intern Med. 2012; 271: 177-178
- Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials.BMJ. 2010; 340: c712
- Safety of the HPV bivalent and quadrivalent vaccines during pregnancy (February).Ann Pharmacother. 2011; 45: 258-262
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.Br J Cancer. 2011; 105: 28-37
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine.Hum Vaccin Immunotherapeutics. 2012; 8: 390-397
- Report of the HPV Vaccine Delivery Meeting Identifying Needs for Implementation & Research. WHO. 2012 ([Geneva], WHO/IVB/12.09)
- Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.Vaccine. 2012; 31: 109-113
- Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.Sex Transm Infect. 2009; 85: 499-502
- Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register.Australia Sex Health. 2011; 8: 171-178
- The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.Sex Transm Infect. 2011; 87: 544-547
- Fall in human papillomavirus prevalence following a national vaccination program.J Infect Dis. 2012; 206: 1645-1651
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study.Lancet. 2011; 377: 2085-2092
- Quadrivalent Human Papillomavirus Vaccine—Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR. 2007; 56: 1-24
- FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP).MMWR. 2010; 59: 626-629
- Human papillomavirus vaccine introduction–The first five years.Vaccine. 2012; 30: F139-F148
- Vaccination coverage among U.S. adolescents aged 13-17 years eligible for the Vaccines for Children program, 2009.Public Health Rep. 2011; 126: 124-134
- An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010.Vaccine. 2012; 30: 3534-3540
- Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital.Vaccine. 2011; 29: 3767-3772
- Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels.J Natl Cancer Inst. 2013; 105: 175-201
- The HPV vaccine impact monitoring project (HPV-IMPACT): Assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions.Cancer Causes Control. 2012; 23: 281-288
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.Lancet Oncol. 2012; 13: 89-99
- Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.Vaccine. 2006; 24 (S3/233-241)
- Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark.Vaccine. 2011; 29: 9663-9667
- Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.Sex Transm Dis. 2013; 40: 130-135
- Introduction of human papillomavirus vaccination in Nordic countries.Vaccine. 2012; 30: 1425-1433
- Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses.PLoS Med. 2006; 3: e138
- Perspective: Vaccinate boys too.Nature. 2012; 488: S10
- Sex-specific immunization for sexually transmitted infections such as human papillomavirus: Insights from mathematical models.PLoS Med. 2011; 8: e1001147
- Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.BMJ. 2009; 339: b3884
- The natural history of cervical HPV infection: unresolved issues.Nat Rev Cancer. 2007; 7: 11-22
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis.Lancet Infect Dis. 2007; 7: 453-459
- Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.J Infect Dis. 2011; 204: 377-384
- Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.Ann Intern Med. 2009; 151: 538-545
- HPV vaccination against cervical cancer in women above 25 years of age: Key considerations and current perspectives.Gynecol Oncol. 2009; 115: S15-S23
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up.Hum Vaccin Immunotherapeutics. 2012; 8: 390-397
- Immunization with virus-like particles from cottontail tabbit papillomavirus (Crpv) Can Protect against experimental Crpv infection.J Virol. 1995; 69: 3959-3963
- In vivo mechanisms of vaccine-induced protection against HPV infection.Cell Host Microbe. 2010; 8: 260-270
- Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.Exp Mol Pathol. 2000; 68: 147-151
- Study of cell-mediated response in mice by HPV 16 L1 virus-like particles expressed in Saccharomyces cerevisiae.J Microbiol Biotechnol. 2007; 17: 1738-1741
- Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: A randomized trial.JAMA. 2007; 298: 743-753
- Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: Findings from CDC focus group research and implications for practice.Health Educ Behav. 2007; 34: 471-485
- Factors that are associated with parental acceptance of human papillomavirus vaccines: A randomized intervention study of written information about HPV.Pediatrics. 2006; 117: 1486-1493
- Human papillomavirus vaccination and sexual behaviour: Cross-sectional and longitudinal surveys conducted in England.Vaccine. 2012; 30: 4939-4944
- Against which human papillomavirus types shall we vaccinate and screen? The international perspective.Int J Cancer. 2004; 111: 278-285
- Vaccine-induced pathogen strain replacement: What are the mechanisms?.J R Soc Interface. 2008; 5: 3-13
- Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.Int J Cancer. 2012; 131: 2832-2838
- Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.J Infect Dis. 2012; 206: 669-677
- Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.J Virol. 2007; 81: 8784-8792
- Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae.Virology. 1995; 209: 506-518
- Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation.Vaccine. 1995; 13: 1509-1514
- Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.Virology. 1995; 206: 126-135
- Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae.Gene. 1996; 180: 1-6
- Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.Virology. 1991; 185: 251-257
- Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.J Virol. 1993; 67: 6929-6936
- Crystal structures of four types of human papillomavirus L1 capsid proteins: Understanding the specificity of neutralizing monoclonal antibodies.J Biol Chem. 2007; 282: 31803-31811
- Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.J Virol. 2008; 82: 12565-12568
- The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.J Biol Chem. 1999; 274: 5810-5822
- A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.CVI. 2012; 19: 1075-1082
- Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.J Virol. 2001; 75: 10493-10497
- Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes.PLoS One. 2009; 4: e4463
- Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.Virology. 2012; 434: 110-117
- Genital human papillomavirus infections: Current and prospective therapies.J Gen Virol. 2012; 93: 681-691
- Therapeutic vaccination against human papilloma virus induced malignancies.Curr Opin Immunol. 2011; 23: 252-257
- Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1.J Molecular Biol. 2001; 307: 173-182
- A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than virus-like particles with respect to the induced antibody response.J Virol. 2008; 82: 5472-5485
- Analysis of modified human papillomavirus type 16 L1 capsomeres: The ability to assemble into larger particles correlates with higher immunogenicity.J Virol. 2009; 83: 7690-7705
- Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.PLoS Pathog. 2009; 5: e1000373
- Expression of hepatitis B surface antigen in transgenic plants.Proc Natl Acad Sci U S A. 1992; 89: 11745-11749
- Immunogenicity of transgenic plant-derived hepatitis B surface antigen.Proc Natl Acad Sci U S A. 1995; 92: 3358-3361
- Comparative analysis of recombinant human papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods.Plant Biotechnol J. 2012; 10: 410-421
- Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants.BMC Biotechnol. 2011; 11: 106
- Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: Transplastomic plants show pleiotropic phenotypes.Plant Biotechnol J. 2011; 9: 651-660
- An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.Virol J. 2009; 6: 2
- Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco.Transgenic Res. 2008; 17: 1091-1102
- Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic.Plant Biotechnol J. 2008; 6: 427-441
- Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.BMC Biotechnol. 2007; 7: 56
- Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: Comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization.J Gen Virol. 2007; 88: 1460-1469
- Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: A proof-of-concept study.CVI. 2006; 13: 845-853
- Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector.Virus Res. 2006; 120: 91-96
- Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants.Acta Biochim Biophys Sin (Shanghai). 2005; 37: 153-158
- Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system.Biomaterials. 2011; 32: 4621-4629
- In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.Vaccine. 2009; 28: 120-131
- Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.Vaccine. 2010; 28: 1613-1619
- DNA vaccine against hamster oral papillomavirus-associated oral cancer.J Int Med Res. 2005; 33: 647-653
- DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants.Genet Vaccines Ther. 2008; 6: 4
- Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the cottontail rabbit papillomavirus model.Viral Immunol. 2006; 19: 492-507
- Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2.Antiviral Res. 2003; 59: 61-65
- Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination.J Gen Virol. 2002; 83: 2299-2301
- Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.Vaccine. 2001; 19: 2783-2792
- DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro.J Med Virol. 2000; 60: 200-204
- Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization.Vaccine. 2000; 19: 227-233
- Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.J Virol. 2001; 75: 9201-9209
- A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression.Nat Med. 2005; 11: 899-904
- Response of mouse skin to tattooing: Use of SKH-1 mice as a surrogate model for human tattooing.Toxicol Appl Pharmacol. 2005; 209: 145-158
- Prophylactic DNA immunization against multiple papillomavirus types.Vaccine. 2007; 25: 4540-4553
- Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.Am J Pathol. 2009; 174: 136-143
- Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.J Virol. 2002; 76: 8900-8909
- Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.J Virol. 2004; 78: 3196-3199
- Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Proc Natl Acad Sci U S A. 2005; 102: 4590-4595
- Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.Virology. 1992; 187: 612-619
- Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in Rhesus Macaques.Hum Gene Ther. 2012; 23: 733-741
- Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.Antivir Ther. 2009; 14: 1125-1137
- Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.J Virol. 2006; 80: 2621-2630
- Efficiency of HPV 16 L1/E7 DNA immunization: Influence of cellular localization and capsid assembly.Vaccine. 2006; 24: 2952-2965
- Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.Int J Cancer. 2013; 132: E139-E148
- A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease.Virology. 1997; 234: 261-266
- Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2.Virology. 2005; 337: 365-372
- A protective and broadly cross-neutralizing epitope of human papillomavirus L2.J Virol. 2007; 81: 13927-13931
- Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.J Virol. 2007; 81: 11585-11592
- Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).Vaccine. 2004; 22: 2722-2729
- Neutralization of HPV 16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV 16 minor capsid protein L2 surface region.Virology. 2007; 358: 266-272
- Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.J Virol. 1999; 73: 6188-6190
- Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.Vaccine. 2001; 19: 1496-1502
- Potent anti-HPV immune responses induced by tandem repeats of the HPV 16 L2 (20–38) peptide displayed on bacterial thioredoxin.Vaccine. 2009; 27: 1949-1956
- A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.Virology. 1998; 245: 353-359
- Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.Proc Natl Acad Sci USA. 2008; 105: 5850-5855
- Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.J Natl Cancer Inst. 2009; 101: 782-792
- A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.PLoS One. 2011; 6: e23310
- Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.Vaccine. 2010; 28: 4384-4393
- Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.J Virol. 2009; 83: 10085-10095
- The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.Virology. 2011; 409: 348-359
Article info
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
